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Glioblastoma multiforme (GBM, World Health Organization/WHO grade IV) is the most common form of 
brain cancer in the central nervous system. Although conventional treatment-surgery, radiation, and 
temozolomide-is somewhat effective in adults, overall survival is still < 15 months. In pediatric patients, 
morbidity due to GBM is the highest among all pediatric cancers. In the context of brain cancers, new 
and existing therapeutics typically fail due to heterogeneity of genetic mutations within tumors, and 
because biologically effective doses of drug cannot be delivered to the primary site and invasive 
perimeter of the tumor due to the blood brain barrier. The Signature Center Initiative to Cure GBM is a 
funding mechanism that supports a research portal to foster investigations of the Brain Tumor Working 
Group for development of effective treatments for the eradication of GBM. The overall mission of the 
Signature Center Initiative is to: 
 
1. Interrogate the molecular mechanisms of GBM biology and develop interventions that result in 
improved duration and quality of life for our patients. 
2. Stimulate consistent and productive exchange of ideas between clinicians and basic scientists while 
employing bench-to-bedside and bedside-to-bench strategies to generate and prioritize scientific 
questions. 
3. Provide infrastructure and mentorship needed to successfully compete for external funding. 
4. Engage the community through patient advocacy to positively impact brain cancer patient 
outcomes and enhance philanthropic initiatives. 
 
The Brain Tumor Working Group brings together scientists committed to engaging in a team-based 
approach to study GBM biology. Infrastructure required to advance in vivo humanized intracranial 
tumor models, drug delivery, target validation, and development of new therapeutic strategies are in 
place. Additionally a patient sample pipeline to obtain, analyze, and distribute primary patient GBM 
specimens from the operating room to the research laboratory has been established. In year one of 
funding, over $70,000 in pilot project funding derived from the Signature Center Initiative and private 
donations has been distributed to the membership. The Brain Tumor Working Group meets in both 
small and large group formats to strategize experimental design and grant submissions.  A network of 
basic scientists and clinicians has been developed that provides an effective forum for addressing 
clinically relevant questions related to GBM. A team-based approach, scientific expertise, and continued 
development of infrastructure provide our membership with a critical foundation to obtain new 
knowledge related to understanding how GBM cells evade therapy. In the future, this information can 
be applied to development of effective treatments that will cure GBM. 
